蒂尔泽帕提德对2型糖尿病患者体脂分布模式的影响
Bertrand Cariou1, Jennifer Linge2,3, Ian J Neeland4
1Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
Diabetes, obesity & metabolism
|March 26, 2024
概括
在2型糖尿病 (T2D) 患者中,提尔泽帕提德治疗显著减少了内脏脂肪组织 (VAT) 和肝脂肪 (LF),使脂肪分布向更平衡的模式转移. 这项研究强调了提泽帕提德改善代谢健康的潜力.
科学领域:
- 代谢性疾病研究研究.
- 医学成像分析分析 医学成像分析
- 药理干预措施 药理干预措施
背景情况:
- 2型糖尿病 (T2D) 与脂肪分布异常有关.
- 评估独立于体重指数 (BMI) 的脂肪分布对于理解T2D至关重要.
- 在SURPASS-3MRI子研究中,研究了T2D患者的脂肪分布变化.
研究的目的:
- 用MRI来描述T2D患者的脂肪分布模式.
- 将T2D患者的脂肪分布与性别和BMI匹配的虚拟对照组 (VCGs) 进行比较.
- 为了评估脂肪分布在52周治疗时的变化,使用蒂尔泽帕蒂德或胰岛素降级剂 (IDeg).
主要方法:
- 利用了SURPASS-3子研究中296名T2D参与者的MRI数据.
- 来自英国生物银行成像研究的确定的VCG (每个≥150名参与者).
- 计算了在基线和第52周内内脏脂肪组织 (VAT),腹部皮下脂肪组织 (aSAT) 和肝脂肪 (LF) 的标准化z-score.
主要成果:
- 与VCG相比,T2D参与者表现出更高的基线增值税和LF.
- 提尔泽帕提德治疗导致z-VAT和z-LF的显著降低,而z-aSAT的增加.
- 胰岛素降解剂治疗仅导致z-LF显著减少.
结论:
- 蒂尔泽帕提德治疗促进了对T2D患者更平衡的脂肪分布的转变.
- 在Tirzepatide的使用中,观察到增值税和生活费的显著降低.
- 这些发现表明,提泽帕提德在改变T2D中的脂肪分布模式方面具有有效性.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Cholesterol: Significance and Regulation
543
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
543
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169


